Paternal valproate use does not increase child neurodevelopmental risk

Paternal valproate use does not increase child neurodevelopmental risk

A comprehensive review and meta-analysis of existing research has found no evidence that men's use of the anti-seizure medication valproate increases the risk of neurodevelopmental disorders, such as autism and ADHD, in their children. The study, which combined data from large population-based studies in Denmark, Norway, Sweden, and Taiwan, analyzed the effects of paternal valproate use on offspring and found no significant link between the two. According to the researchers, the findings raise questions about the basis for current European precautionary measures, which were introduced in 2024 following a study suggesting a potential increased risk of neurodevelopmental disorders in children of fathers treated with valproate. The new analysis, however, found no increased risk of neurodevelopmental disorders, either overall or for specific conditions such as autism and ADHD. The researchers note that differences between earlier and more recent findings may be explained by methodological differences, including how the data were analyzed and adjusted for other influencing factors. They emphasize that treatment choices must always be based on an overall assessment of benefits and risks, and that valproate remains an effective treatment for many patients with epilepsy. The study's findings have been welcomed by patient groups, who have expressed concern about the potential impact of precautionary measures on patients' treatment options. Tom Shillito, health improvement and research manager at Epilepsy Action, said that the new study provides "encouraging" evidence that men taking valproate are not at increased risk of neurodevelopmental disorders in their children, and that it is time for the Medicines and Healthcare products Regulatory Agency (MHRA) to reconsider the evidence and give it consideration. The MHRA had previously issued advice recommending that male patients and their female partners use effective contraception during valproate use, following a study that suggested a possible connection between use of valproate in men and a small increased risk of neurodevelopmental disorders in their children. However, the new study's findings suggest that this risk may not be significant, and that valproate can be a safe and effective treatment option for men with epilepsy. In light of the new findings, patient groups and clinicians are urging a reassessment of current guidelines and recommendations. The study is designed as a living meta-analysis, meaning that it will be continuously updated as new research becomes available. This will provide clinicians and patients with the most up-to-date information and guidance on the use of valproate and its potential effects on offspring.